Keratosis Pilaris
Conditions
Brief summary
The purpose of this study is to demonstrate the safety, tolerability and efficacy of AO+ Mist administered daily for 4 weeks to improve the appearance of skin afflicted with keratosis pilaris.
Detailed description
This will be a single center, double-blind, placebo-controlled study in subjects with keratosis pilaris affecting both sides of the body. Subjects will be screened within 4 weeks of enrollment. Subjects will be seen at the research facility on for the baseline visit and will be asked to return to the site on weeks 1, 2, 3 and 4 for assessments. Test product application will occur for four weeks starting with the day of the baseline visit.
Interventions
OTHERPlacebo
Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows: * LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. * RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. * Subjects may not wash their body with soap and water AFTER the applications
OTHERAO+Mist
Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows: * LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. * RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days. * Subjects may not wash their body with soap and water AFTER the applications
Sponsors
AOBiome LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Caregiver)
Masking description
AO+ Mist (or placebo) are supplied in white 100mL metered spray bottles. Test products are blinded and labeled for application to the LEFT or RIGHT side of the body.
Intervention model description
Bi-Lateral study
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Male and female subjects ≥18 and ≤65 years of age 2. Subject is in good general health 3. Diagnosis of keratosis pilaris involving areas of the body affected bilaterally 4. Subject has Fitzpatrick Skin Type I-VI 5. Willing to refrain from using any treatments, other than the investigational product, including antibiotics, for acne present on the face. 6. Ability to comprehend and comply with procedures 7. Agree to commit to participate in the current protocol 8. Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)
Exclusion criteria
1. Male and female subjects under 18 years or over 65 years of age 2. Female subjects who are pregnant or lactating 3. Subjects who have received laser therapy to the KP affected area in the past 1 year 4. Subjects with a concurrent diagnosis of another skin condition or malignancy 5. Subjects with tan or sunburn over the area affected by KPin the past month 6. Subjects with open, non-healing sores or infections at any skin site 7. Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid, including lactic acid lotions (Am-Lactin, Lac-Hydrin), urea cream (Carmol 10, Carmol 20, Carmol 40, Urix 40), salicylic acid (Salex lotion), topical corticosteroids within 4 weeks prior to baseline. 8. Treatment with systemic corticosteroids (including intranasal and inhaled corticosteroids) within 4 weeks prior to baseline 9. Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to baseline 10. Prescription topical retinoid use on the face or body within 4 weeks of baseline (e.g., tretinoin, tazarotene, adapalene). 11. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline.. 12. Treatment with any investigational drug within 30 days prior to the beginning of the screening period (this includes investigational formulations of marketed products, inhaled and topical drugs) 13. Subjects who are unable to understand the protocol or give informed consent 14. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Treatment-Related Adverse Events as assessed by physical exam and appearance | Baseline-Week 4 |
Secondary
| Measure | Time frame |
|---|---|
| Difference in Keratosis pilaris Investigator Score | Baseline-Week 4 |
Other
| Measure | Time frame |
|---|---|
| Difference in Skindex16 Quality of Life survey | Baseline-Week 4 |
Countries
United States
Outcome results
None listed